Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 09, 2021

SELL
$18.57 - $35.68 $1.06 Million - $2.03 Million
-56,975 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$31.0 - $55.72 $40,300 - $72,436
-1,300 Reduced 2.23%
56,975 $1.98 Million
Q4 2020

Feb 09, 2021

SELL
$37.09 - $48.97 $828,479 - $1.09 Million
-22,337 Reduced 27.71%
58,275 $2.16 Million
Q3 2020

Nov 09, 2020

BUY
$40.47 - $45.5 $1.64 Million - $1.84 Million
40,508 Added 101.01%
80,612 $3.31 Million
Q2 2020

Aug 12, 2020

BUY
$32.57 - $42.83 $543,788 - $715,089
16,696 Added 71.33%
40,104 $1.63 Million
Q1 2020

May 04, 2020

SELL
$23.3 - $45.96 $1,165 - $2,298
-50 Reduced 0.21%
23,408 $813,000
Q4 2019

Feb 12, 2020

SELL
$34.58 - $48.06 $538,998 - $749,111
-15,587 Reduced 39.92%
23,458 $1.01 Million
Q3 2019

Nov 12, 2019

SELL
$36.98 - $48.45 $18,490 - $24,225
-500 Reduced 1.26%
39,045 $1.44 Million
Q2 2019

Aug 16, 2019

SELL
$35.13 - $55.53 $14,052 - $22,212
-400 Reduced 1.0%
39,545 $1.79 Million
Q1 2019

May 13, 2019

SELL
$42.83 - $59.91 $130,288 - $182,246
-3,042 Reduced 7.08%
39,945 $2.17 Million
Q4 2018

Feb 05, 2019

BUY
$37.97 - $60.16 $631,403 - $1 Million
16,629 Added 63.09%
42,987 $1.99 Million
Q3 2018

Nov 07, 2018

SELL
$56.3 - $67.25 $40,310 - $48,151
-716 Reduced 2.64%
26,358 $1.6 Million
Q2 2018

Aug 10, 2018

SELL
$44.9 - $64.95 $31,834 - $46,049
-709 Reduced 2.55%
27,074 $1.7 Million
Q1 2018

May 08, 2018

BUY
$45.35 - $61.65 $9,070 - $12,330
200 Added 0.73%
27,783 $1.28 Million
Q4 2017

Feb 13, 2018

SELL
$41.95 - $60.1 $544,427 - $779,977
-12,978 Reduced 32.0%
27,583 $1.31 Million
Q3 2017

Nov 07, 2017

SELL
$33.4 - $53.9 $1.44 Million - $2.33 Million
-43,152 Reduced 51.55%
40,561 $2.18 Million
Q2 2017

Nov 20, 2017

BUY
N/A
83,713
83,713 $2.7 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Clari Vest Asset Management LLC Portfolio

Follow Clari Vest Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clari Vest Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clari Vest Asset Management LLC with notifications on news.